Shots:

• The P-III SOLO-1 study involves assessing of Lynparza (300mg- bid) as a maintenance monothx. vs PBO in 391 patients in a ratio (2:1) with newly diagnosed BRCAm advanced ovarian cancer following 1L Pt.-based CT for ~2yrs. or until disease progression
• Five-year follow-up data demonstrated a 67% reduction in risk of disease progression or death- improvement in PFS (56 vs 13.8mos.)- patients remained free from disease progression (48.3% vs 20.5%)- the median duration of treatment (24.6 vs 13.9mos.)- presented at ESMO 2020
• The P-III SOLO-1 met its 1EPs of PFS in Jun’2018- which formed the basis of approvals in the US- the EU- Japan- China- and other countries. Lynparza is a first-in-class PARP inhibitor acts by targeting DDR in cells/tumors harboring a deficiency in HRR (BRCA1& 2 mutation)

­ Ref: AstraZeneca | Image: Mint